The M2 splice isoform of pyruvate kinase is a phosphotyrosine binding protein critical for tumor cell metabolism and proliferation
By: by Heather Renee Christofk
Series: Collections of the Harvard University Archives
Published: 2007
Language: eng
Number of pages: 131
Description: Using a proteomic screen, we have discovered that binding of tyrosine phosphorylated peptides to the M2 isoform of pyruvate kinase regulates its enzymatic activity and is critical for cancer cell proliferation. We have developed a mass spectrometry proteomics approach for identifying phosphopeptide binding proteins from cell lysates. By combining a quantitative proteomic strategy, stable isotope labeling of amino acids in cell culture (SILAC), with immobilized peptide library technology, we have found that the glycolytic protein, pyruvate kinase, binds selectively to tyrosine-phosphorylated peptides. Interestingly, binding to phosphoTyr peptides is specific to the M2 fetal isoform of pyruvate kinase (PKM2), which has been found to be expressed in tumor cells and all proliferating cells examined. Binding of phosphoTyr peptides to PKM2 results in release of the allosteric activator, fructose-1,6-bisphosphate, and the subsequent inhibition of PKM2 enzymatic activity. Importantly, we have found that a variety of stimuli that activate protein tyrosine kinases in cells inhibit the activity of endogenous PKM2 but do not affect the activities of other pyruvate kinase isoforms or a point mutant of PKM2 that cannot bind to phosphoTyr peptides. Replacement of endogenous PKM2 with a point mutant that cannot bind phosphoTyr peptides impairs cell growth, indicating that regulation of PKM2 activity via phosphoTyr peptide binding is essential for cancer cell proliferation. These results suggest a novel mechanism by which growth factor receptor protein tyrosine kinases regulate PKM2 that involves release of trapped FBP due to collision with tyrosine-phosphorylated proteins.

We have found that switching splice isoform expression to the M2 isoform of pyruvate kinase in cancer cells is necessary for the shift in cellular metabolism to aerobic glycolysis and promotes tumorigenesis. Tumor cells metabolize glucose by aerobic glycolysis. Also known as the Warburg effect, aerobic glycolysis is characterized by increased glycolytic activity with concomitant lactate production and reduced oxidative phophorylation even under aerobic (normoxic) conditions. How tumor cells establish this altered metabolic phenotype and whether it is essential for tumorigenesis is yet unknown. Replacement of the M2 isoform in cancer cell lines with the adult M1 isoform leads to reversal of the Warburg effect as judged by reduced lactate production and increased oxygen consumption, as well as a reduced ability to form tumors in nude mouse xenografts. These results demonstrate that M2 expression is necessary for aerobic glycolysis and that this metabolic phenotype provides a selective growth advantage for tumor cells in vivo . Together, our findings reveal a critical role for PKM2 in tumor cell proliferation and metabolism. We identify PKM2 to be an attractive novel cancer drug target and propose that PKM2 represents an important link between tyrosine kinase signaling and metabolic control in proliferating cells.
Notes: "August 2007."

Thesis (Ph.D., Division of Medical Sciences (Cell and Developmental Biology))--Harvard University, 2007.

Includes bibliographical references.